Skip to content
value.today

cbdMD, Inc.

YCBD
$4 Mmarket cap on Oct 30, 2026+45.7% since Jan 2024
Compare
World rank
#27,060
Revenue
$19 M
For year ending September-2025
Net income
$-2 M
-10.6% margin
SEC filing
Employees
42
As of September 30, 2025
SEC filing

cbdMD, Inc. in brief

cbdMD, Inc. is a listed company in the Pharmaceutical industry, based in Charlotte, North Carolina, USA. Its market value was $4 M on 30 October 2026, which makes it the 27,060th largest listed company in the world and the 4,424th largest in the USA on this site. In the year to September 2025 it had sales of $19 M and a net loss of $2 M. It employs about 42 people and Ronan Kennedy is its chief executive. Its shares trade under the symbol YCBD (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

cbdMD, Inc. timeline

5 events, 2015–2021
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2016
  4. ✎
    Renamed Level Brands, Inc.
    Formerly Level Beauty Group, Inc..
  5. 2017
  6. 🔔
    · approximate
    Initial public offering on NYSE
  7. 2019
  8. ✎
    Renamed cbdMD, Inc.
    Formerly Level Brands, Inc..
  9. 2021
  10. 💰
    Record revenue of $44 million
    FY2021, the highest of the 8 years on record.

Events of cbdMD, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$42 M$83 M$125 M$166 M2020202120222023202420252026

World rank over time

▼ down 6,588 places since 2020
2020-01-01: #20479#20,47920202021-01-01: #16517#16,51720212022-01-07: #25475#25,47520222022-12-25: #30260#30,26020222023-07-30: #33247#33,24720232024-01-05: #33166#33,16620242026-03-08: #12893#12,89320262026-08-01: #23608#23,60820262026-09-22: #26980#26,98020262026-10-30: #27067#27,0672026

Rank in USA: #3,933 (Jan 2020) · #3,419 (Jan 2021) · #4,776 (Jan 2022) · #5,407 (Dec 2022) · #5,654 (Jul 2023) · #4,685 (Jan 2024) · #2,400 (Mar 2026) · #4,124 (Aug 2026) · #4,359 (Sep 2026) · #4,424 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.2×
Price / book
0.6×
Free cash flow yield
-37.3%
Net margin (TTM)
-13.8%
Operating margin
-11.3%
Return on equity
-40.0%
Liabilities / assets
30.6%
Net debt
$-2M
Revenue growth
-1.5%
Revenue per employee
$457 K
Profit per employee
$-49 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $0M, net income $0M$0MFY18Fiscal year ending Sep 2019: revenue $24M, net income $-51M$24MFY19Fiscal year ending Sep 2020: revenue $42M, net income $13M$42MFY20Fiscal year ending Sep 2021: revenue $44M, net income $-23M$44MFY21Fiscal year ending Sep 2022: revenue $35M, net income $-70M$35MFY22Fiscal year ending Sep 2023: revenue $24M, net income $-23M$24MFY23Fiscal year ending Sep 2024: revenue $19M, net income $-4M$19MFY24Fiscal year ending Sep 2025: revenue $19M, net income $-2M$19MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025$19M-1.5%$-2M$-2M-10.6%
Sep 2024$19M-19.4%$-3M$-4M-19.0%
Sep 2023$24M-31.8%$-22M$-23M-95.0%
Sep 2022$35M-20.4%$-78M$-70M-198.0%
Sep 2021$44M+6.2%$-20M$-23M-52.6%
Sep 2020$42M+77.1%$-18M$13M30.1%
Sep 2019$24M+5041.3%$-15M$-51M-217.2%
Sep 2018$0M—$-2M$0M13.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-1M$0M$-2M$-1.09—
Sep 2024$-0M$0M$-1M$-14.29—
Sep 2023$-4M$0M$-5M$-13.32—
Sep 2022$-15M$1M$-16M$-55.80—
Sep 2021$-14M$0M$-14M$-0.47—
Sep 2020$-11M$1M$-12M$0.28—
Sep 2019$-15M$1M$-17M$0.00—
Sep 2018$-6M$0M$-6M$0.00—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$21M
Net income, trailing 12 months
$-3M
RevenueNet income
Three months to Sep 2024: revenue —, net income $-0M—Sep ’24Three months to Dec 2024: revenue $5M, net income $0M$5MDec ’24Three months to Mar 2025: revenue $5M, net income $-0M$5MMar ’25Three months to Jun 2025: revenue $5M, net income $-1M$5MJun ’25Three months to Sep 2025 (from the annual report): revenue $5M, net income $-1M$5MSep ’25Three months to Dec 2025: revenue $5M, net income $-0M$5MDec ’25Three months to Mar 2026: revenue $6M, net income $-1M$6MMar ’26Three months to Jun 2026: revenue $6M, net income $-1M$6MJun ’26

Latest quarter to Jun 2026: revenue $6M (+20.4% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of cbdMD, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$19 M
Operating income
$-2 M
Net income
$-2 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$3 M
Total equity
$7 M

As of September-2025

Top 27 institutional investors in cbdMD, Inc.#

As of Sep 30, 2026
27 institutions held 861,451 shares (about 7.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 6.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in cbdMD, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1CSS Llc/il137,6210 (0.00%)1.23%$0 MNov 16, 2026
2Vanguard Capital Management LLC119,6450 (0.00%)1.07%$0 MNov 13, 2026
3HRT Financial LP97,538New0.87%$0 MNov 13, 2026
4Citadel Advisors LLC92,971New0.83%$0 MNov 16, 2026
5Chapin Davis, Inc.81,2500 (0.00%)0.73%$0 MOct 9, 2026
6Alesco Advisors, LLC, An ESL Co68,5130 (0.00%)0.61%$0 MNov 16, 2026
7Vanguard Fiduciary Trust Co47,1570 (0.00%)0.42%$0 MNov 13, 2026
8Jane Street Group, LLC45,023-9,378 (-17.24%)0.40%$0 MNov 12, 2026
9Chicago Partners Investment Group LLC37,275-40,823 (-52.27%)0.33%$0 MOct 27, 2026
10Virtu Financial LLC35,941+25,450 (+242.59%)0.32%$0 MNov 17, 2026
11Susquehanna International Group, LLP19,783New0.18%$0 MNov 16, 2026
12UBS Group AG18,344-3,232 (-14.98%)0.16%$0 MNov 10, 2026
13StoneX Group Inc.16,335+3,603 (+28.30%)0.15%$0 MNov 3, 2026
14Commonwealth Equity Services, LLC16,2550 (0.00%)0.15%$0 MNov 2, 2026
15Northern Trust Corp10,307-4,596 (-30.84%)0.09%$0 MNov 16, 2026
16Beacon Pointe Advisors, LLC10,000New0.09%$0 MNov 16, 2026
17Harbour Investments, Inc.5,2000 (0.00%)0.05%$0 MNov 9, 2026
18Morgan Stanley1,1390 (0.00%)0.01%$0 MNov 13, 2026
19BlackRock, Inc.1,0800 (0.00%)0.01%$0 MNov 13, 2026
20Osaic Holdings, Inc.49-14 (-22.22%)0.00%$0 MNov 12, 2026
21HHM Wealth Advisors, LLC80 (0.00%)0.00%$0 MNov 10, 2026
22Pinnacle Financial Group, Inc.8—0.00%$0 MNov 16, 2026
23Farther Finance Advisors, LLC30 (0.00%)0.00%$0 MOct 8, 2026
24Group One Trading LLC20 (0.00%)0.00%$0 MNov 10, 2026
25Golden State Wealth Management, LLC20 (0.00%)0.00%$0 MNov 2, 2026
Show all 27: investors 26 to 27
Institutional investors 26 to 27 in cbdMD, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Rothschild Investment LLC10 (0.00%)0.00%$0 MNov 10, 2026
27Rockefeller Capital Management L.P.10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding cbdMD, Inc.#

2 funds hold shares worth $0 M (about 1.1% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding cbdMD, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.119,645$0 M1.1%<0.01%+134%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC1,123$0 M0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at cbdMD, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$1.3 M
3 sales, 1 insider
Net, 12 months
-$1.3 M
open market only
Insiders on file
20
since
cbdMD, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed William F. Raines IIIDirectorGrant or award+1,572——13,676Form 4
filed Jeffrey H. PorterDirectorGrant or award+1,572——3,144Form 4
filed Sibyl Nichole SwiftDirectorGrant or award+1,572——4,145Form 4
filed Bakari T. SellersDirectorGrant or award+1,572——4,324Form 4
filed Kevin Charles RoeDirectorGrant or award+1,572——26,707Form 4
filed Scott G. StephenDirectorGrant or award+1,572——4,412Form 4
filed Clark R. Crosnoe10% ownerSellindirect-461,725$2.310$1.1 M361,400Form 4
filed Clark R. Crosnoe10% ownerSellindirect-69,875$2.340$164 K56,875Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: cbdMD, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
482,585
5.4% of shares · 7.4 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-12-19 19:05 UTC, code T3, resumed 20:20 UTC
  • 2025-12-18 18:53 UTC, code M, resumed 18:58 UTC
  • 2025-12-12 14:52 UTC, code M, resumed 14:57 UTC
  • 2025-09-29 15:26 UTC, code M, resumed 15:31 UTC
  • 2025-09-29 14:49 UTC, code M, resumed 14:54 UTC

Fails to deliver

  • : 7,524 shares at $0.39
  • : 339 shares at $0.36
  • : 406 shares at $0.37
  • : 7,805 shares at $0.39
  • : 68,968 shares at $0.44

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

cbdMD, Inc. scorecard#

Passes 4 of the 19 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%-37.3%Free cash flow is -37.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-1.5%Revenue down 1.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-18.5%-18.5% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-18.5%-18.5% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-1.09 vs -14.29Diluted EPS -1.09 in fiscal 2025 against -14.29 the year before (report's currency).
    • ✗Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against $13 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-11.3%-11.3% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-44.4%-44.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-11.3%-11.3% in fiscal 2025 against -221.1% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.05 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-21.74Z-score -21.74 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from cbdMD, Inc.'s statements, beside the median of Pharmaceutical.

cbdMD, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-11.3%1.8%
Net margin-10.6%-1.5%
Return on equity-44.4%-0.9%
Revenue growth, 3 years a year-18.5%2.5%
Revenue growth-1.5%7.3%
Free cash flow margin-8.5%6.0%

5of 8on the Piotroski tests of financial strength

  • Revenue fell 1.5% against the year before.
  • Net loss of $2 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$2 million.
  • Receivables grew 27% while revenue grew -1%: customers are paying later, or sales were booked ahead of cash.

cbdMD, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

cbdMD, Inc.: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue191924354442240.5r4.52.0
Cost of revenue7.27.59.21314169.10.1r1.41.6
Gross profit121215223026r150.4r3.10.4
Operating expenses————5044292.2r3.44.1
Operating income−2.2−3.3−22−78−20−18r−15−1.8r−1.4−3.9
Interest expense and finance costs———————0.00.50.2
Net interest income0.0−0.00.10.0−0.00.00.10——
Other non-operating income (expense)——00.20.0—————
Income before tax−2.0−3.7−23−70−2411r−48−1.8——
Income tax0000−0.9r1.3r−2.40r0.00.0
Income from continuing operations—————13−45−1.8r−0.2−3.7
Income from discontinued operations————0−0.0−5.91.9——
Net income including minority interests———————0.1−1.4−3.9
Net income attributable to shareholders−2.0−3.7−23−70−2313r−510.1−1.4−3.9
Earnings per share, basic-1.09-14.29r-13.32-55.80r-0.470.28-2.82-0.05-0.38-1.13
Earnings per share, diluted-1.09-14.29r-13.32-55.80r-0.470.280.000.00r-0.38-1.13
Shares, weighted average (basic)4.00.5r2.01.3r5544187.7——
Shares, weighted average (diluted)4.00.5r2.01.3r5545187.7r4.53.0
Balance sheet
Cash and cash equivalents2.32.51.86.726154.74.30.30.0
Short-term investments———00.00.00.21.10—
Receivables0.80.61.2r0.3——00.50—
Inventory2.92.54.2r4.85.64.95.20.10.60.6
Other current assets0.3r0.40.80.71.1—————
Current assets6.66.48.116372416123.71.0
Property, plant and equipment0.30.50.70.82.63.21.70.10.10.2
Right-of-use (leased) assets0.70.13.44.55.66.90———
Goodwill0—005755550——
Other intangible assets2.12.93.2182322223.23.20.5
Total assets1011164112511195157.11.6
Accounts payable1.21.51.92.03.02.93.00.50.40.2
Customer deposits——————0.00——
Current liabilities3.28.64.75.36.97.73.71.01.51.9
Long-term debt——0.00.10.10.3————
Lease liabilities (non-current)002.43.74.96.00———
Non-current liabilities002.54.11524530.00.40.0
Total liabilities3.28.67.29.42232571.01.91.9
Retained earnings−179−182−174−147−73−47−60−6.7−6.3−4.5
Shareholders' equity7.22.09.031103793814r4.20.4
Minority interests——————01.40.9−0.7
Total equity——————38145.1−0.3
Total liabilities and equity1011164112511195157.11.6
Shares outstanding8.90.5r3.01.3r5852288.15.83.4
Cash-flow statement
Depreciation and amortization————1.00.70.30.20.10.0
Share-based compensation————1.31.92.50.60.10.0
Cash from operating activities−1.5−0.4−4.3−15−14−11r−15r−5.6−2.3−2.9
Capital expenditure−0.2−0.2−0.3−0.7−0.3−1.3−1.2−0.0−0.0−0.1
Intangible assets bought0−0.100−2.00−0.1−0.40—
Acquisitions, net of cash acquired—————0−0.90——
Cash from investing activities−0.2−0.30.7−0.7−2.6−1.6−2.1−0.70.2r−0.1
Shares issued00.12.5001719110.82.0
Dividends paid————−2.6−0.40———
Cash from financing activities1.41.3−1.3−4.0282218102.4r2.5
Change in cash————1210r0.44.00.2−0.5
Report10-Q10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at cbdMD, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$300 K
Ronan Kennedy
Other top executives, average
$207 K
the CEO earned 1.4× this
$100 invested is now
—
cbdMD, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Ronan Kennedy$300 K$300 K$207 K—
2024Ronan Kennedy$275 K$275 K$181 K—
2023Kevin MacDermott$385 K$385 K$191 K—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at cbdMD, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 3 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 1

cbdMD, Inc.: events reported to the SEC
FiledWhat happenedFiling
Acquisition or sale completedNew debtUnregistered share sale8-K
Material agreementBylaws or fiscal year changed8-K
Material agreementNew debt8-K
Directors and officersShareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Directors and officers8-K
Material agreementNew debt8-K
Delisting notice8-K/A
Material agreementUnregistered share sale8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

How cbdMD, Inc. compares in Pharmaceutical

  • Market cap$4 M · higher than 3% of 393
  • Revenue$19 M · higher than 8% of 324
  • Net margin-13.8% · higher than 17% of 313
  • Revenue growth-1.5% · higher than 23% of 107
  • Price / sales0.2× · lower than 98% of 219
  • Price / book0.6× · lower than 94% of 207
  • FCF yield-37.3% · higher than 10% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
cbdMD, Inc.🇺🇸$4 M—-13.8%-1.5%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Employees:
As of September 30, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at cbdMD, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show cbdMD, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about cbdMD, Inc.? Suggest a correction